@entity3131 prevents endotoxin-induced XXXX after partial hepatectomy in @entity35 .

@entity5694 @entity15795 @entity648 @entity3131 @entity842 @entity35 @entity99
BACKGROUND/AIMS: Massive liver resection causes a variety of complications including @entity5694 . @entity3131 ( @entity15795 ) is a new experimental drug used as antifibrotic agent. Studies were performed to investigate whether @entity15795 influences the survival rate of animals with endotoxin-induced @entity99 after partial hepatectomy, and the mechanisms involved. METHODS: @entity35 were treated with lipopolysaccharide (LPS) 48 h after 70% hepatectomy. @entity15795 was administered orally before LPS injection. RESULTS: @entity15795 improved the survival rate of LPS-treated @entity35 after hepatectomy. @entity15795 prevented increases in serum enzymes and total @entity648 related to @entity99 . Histopathological analysis revealed that @entity15795 inhibited the enhancement in @entity99 and apoptosis. Further, @entity15795 inhibited increases of inflammatory cytokines and cytokine-induced neutrophil chemoattractant (CINC) in serum and liver, followed by decreases of number of infiltrating neutrophils into liver. Electrophoretic mobility shift assay revealed that @entity15795 inhibited the activation of transcription factor nuclear factor-kappa B (NF-kappa B) induced by LPS. @entity15795 also reduced the induction of inducible @entity842 synthase (iNOS) in the liver of LPS-treated @entity35 . CONCLUSIONS: These results indicate that @entity15795 inhibits the productions of inflammatory cytokines, CINC and iNOS in part through the inhibition of NF-kappa B activation, resulting in the prevention of endotoxin-induced @entity99 after hepatectomy.
